PT  - JOURNAL ARTICLE
AU  - Jirasek, Petr
AU  - Jusku, Alexandr
AU  - Simanek, Vilim
AU  - Frankova, Jana
AU  - Storch, Jan
AU  - Vacek, Jan
TI  - Cannabidiol and periodontal inflammatory disease: A critical assessment
DP  - 2022 May 13
TA  - Biomedical papers
PG  - 155--160
VI  - 166
IP  - 2
AID - 10.5507/bp.2022.012
IS  - 12138118
AB  - Cannabidiol (CBD), a non-psychotropic cannabinoid produced by the genus Cannabis, is a phytoceutical that activates the endocannabinoid system (ECS) through binding to CB1 and CB2 receptors. The ECS is involved in cellular homeostasis and regulates metabolic processes in virtually all mammalian tissues. Published studies on CBD focus, inter alia, on its use in prophylaxis and as an anti-inflammatory agent. Here the authors present a critical assessment of the effects of CBD on inflammatory periodontal diseases caused by bacterial virulence factors, and evaluate critically the possible benefits and drawbacks of CBD use in dentistry. Particular attention is paid to the interaction of CBD with microbially colonized oral tissues, the inflammatory response in relation to the immune response, and the destruction/regeneration of hard and soft tissues of the periodontium.